ADVERTISEMENT

Aarti Drugs Q1 Review - Cost Inflation Headwinds Transient In Nature: Dolat Capital

Aarti Drugs Q1 Review - Cost Inflation Headwinds Transient In Nature: Dolat Capital

<div class="paragraphs"><p>Capsules are arranged for photograph. (Source: pxhere)</p></div>
Capsules are arranged for photograph. (Source: pxhere)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Aarti Drugs Ltd.'s total revenue stood at Rs 6.2 billion (in-line) grew by 7% YoY. Gross margin at 31.0% (in line) declined 64 basis points YoY /17 bps QoQ.

Ebitda stood at Rs 671 million below our estimates and Ebitda margin at 10.8% declined by 295 bps YoY / 159 bps QoQ mainly due to higher other expenses owing to higher power and fuel cost.

Aarti Drugs' profit after tax stood at Rs 348 million below our estimates declined by 28.7% YoY/37.1% QoQ on account of lower than expected operating performance and other income and higher interest charge.

Click on the attachment to read the full report:

Dolat Capital Aarti Drugs Q1FY23 Result update.pdf

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.